RICHMOND, B.C., July 14, 2004 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX): BioCurex is pleased to provide an update on its presentations to the cancer community.
In the past 3 weeks BioCurex has presented results on its blood test (Serum-RECAF(tm)) for cancer detection at the Early Diagnosis Research Network (EDRN), an initiative of the U.S. National Cancer Institute and at the annual meeting of the ISOBM, a prestigious international scientific society dedicated, for the past 32 years, to the detection of cancer markers.
Dr. Moro, President and CEO stated: "Our results were very well received and we were approached by numerous scientists interested in collaborating with us to define RECAF as a marker to detect a variety of cancers. We are now developing these international collaborations, which include groups from high profile institutions in the USA as well as international interest from The Netherlands, Germany and Spain.
"Further, Dr. Taketa's group in Japan, who also presented highly specific and sensitive results using Histo-RECAF(tm) for stomach cancer detection, will expand their project to include other types of cancers."
BioCurex is providing the test kits and each group will then study the expression of RECAF in a particular type of cancer. Some of the tests may take place in BioCurex facilities, in which case the samples will be strictly encoded in a "blind test" to ensure that BioCurex scientists do not know the diagnosis until they have provided the results to the external investigator. These significant collaborations will not only provide additional validation from independent laboratories, but also allow a more effective and efficient method to study thousands of samples of many types of cancer. The information will be valuable in targeting our test to achieve the highest penetration of the technology in the marketplace.
BioCurex was also approached by four dominant companies in the industry at the congresses. In the upcoming weeks, BioCurex will be structuring several programs by which these companies will provide us with encoded samples in order to confidentially validate our claims in unbiased "blind" tests. This procedure is a common and necessary step in the process of licensing any new biotechnology.
Subsequently, BioCurex hopes to establish a research alliance with one or more of these companies in order to modify the test for their specific analytic method as a preamble to a possible licensing agreement.
Dr. Moro commented, "In addition to the interest expressed by scientists, I was very pleased to note significant amounts of interest on behalf of major companies who contacted us. We are in the process of carefully studying their proposals. We are anxious to strike one or more licensing deals, but at the same time, the decisions we will make in the near future will dictate our revenues for many years to come. Thus, we want to do it right."
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX), visit our website at www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.